Literature DB >> 31485577

Prevalence of the UGT1A1*28 promoter polymorphism and breast cancer risk among African American women in Memphis, TN.

Alana Smith1, Cheryl D Cropp2,3, Gregory Vidal4,5, Elizabeth Pritchard5, Jennifer Cordero1, Claire Simpson1, Athena Starlard-Davenport1.   

Abstract

Inherited variations in UDP-glucuronosyltransferase 1A1 (UGT1A1) are associated with an increased breast cancer risk in women of African ancestry. The UGT1A1*28 promoter polymorphism is characterized by the presence of 7 TA repeats in the TATA box sequence and results in reduced UGT1A1 gene expression and enzymatic activity. In this study, we investigated associations between the UGT1A1*28 polymorphism and breast cancer risk among African American (AA) women in Memphis, Tennessee, a city with increased breast cancer mortality rates among AA women. Saliva was collected from 352 AA women, including breast cancer cases (n=82) and controls (n=270) between June 2016 to June 2017. DNA was isolated and sequenced for the UGT1A1*28 polymorphism. The odds ratio for cases with the low UGT1A1 activity alleles (TA)7/8 repeat genotypes versus 5/5, 5/6, and 6/6 genotypes was 1.46 [95% CI, 0.65-3.31; P = 0.36] in premenopausal women and 1.10 (95% CI, 0.52-2.38; P = 0.79) in postmenopausal women. Further analysis of TCGA RNA-seq data showed that UGT1A1 mRNA was significantly lower among estrogen receptor (ER)-negative breast cancers from AA as compared to non-Hispanic white women with ER-negative breast cancer. Larger epidemiological studies are needed to determine the functional consequence of the UGT1A1*28 polymorphism on breast cancer risk in AA women.

Entities:  

Keywords:  African American; Memphis; TN; UGT1A1; UGT1A1*28; breast cancer disparities

Year:  2019        PMID: 31485577      PMCID: PMC6724729          DOI: 10.9777/chd.2019.1015

Source DB:  PubMed          Journal:  Cancer Health Disparities        ISSN: 2573-9530


  25 in total

1.  Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels.

Authors:  C Guillemette; I De Vivo; S E Hankinson; C A Haiman; D Spiegelman; D E Housman; D J Hunter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-06       Impact factor: 4.254

Review 2.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Authors:  R H Tukey; C P Strassburg
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

3.  [Association of polymorphisms in SULT1A1 and UGT1A1 Genes with breast cancer risk and phenotypes in Russian women].

Authors:  E G Shatalova; V I Loginov; E A Braga; T P Kazubskaia; M A Sudomoina; R L Blanchard; O O Favorova
Journal:  Mol Biol (Mosk)       Date:  2006 Mar-Apr

4.  Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans.

Authors:  C Guillemette; R C Millikan; B Newman; D E Housman
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

5.  Phenylalanine(90) and phenylalanine(93) are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10.

Authors:  Athena Starlard-Davenport; Yan Xiong; Stacie Bratton; Anna Gallus-Zawada; Moshe Finel; Anna Radominska-Pandya
Journal:  Steroids       Date:  2006-12-15       Impact factor: 2.668

6.  Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.

Authors:  L Iyer; D Hall; S Das; M A Mortell; J Ramírez; S Kim; A Di Rienzo; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  1999-05       Impact factor: 6.875

7.  Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

Authors:  Cristian Massacesi; Salvatore Terrazzino; Fabiana Marcucci; Marco B Rocchi; Paolo Lippe; Renato Bisonni; Marco Lombardo; Alberta Pilone; Rodolfo Mattioli; Alberta Leon
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

8.  Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.

Authors:  Mark A Boyd; Preeyaporn Srasuebkul; Kiat Ruxrungtham; Peter I Mackenzie; Verawan Uchaipichat; Michael Stek; Joep M A Lange; Praphan Phanuphak; David A Cooper; Wandee Udomuksorn; John O Miners
Journal:  Pharmacogenet Genomics       Date:  2006-05       Impact factor: 2.089

9.  Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer.

Authors:  Olufemi J Adegoke; Xiao Ou Shu; Yu-Tang Gao; Qiuyin Cai; Joan Breyer; Jeffrey Smith; Wei Zheng
Journal:  Breast Cancer Res Treat       Date:  2004-06       Impact factor: 4.872

10.  Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium.

Authors:  Johanie Lépine; Olivier Bernard; Marie Plante; Bernard Têtu; Georges Pelletier; Fernand Labrie; Alain Bélanger; Chantal Guillemette
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

View more
  1 in total

1.  Association of serum bilirubin levels with risk of cancer development and total death.

Authors:  Toyoshi Inoguchi; Naoki Nakashima; Yasunobu Nohara; Chinatsu Nojiri
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.